top of page

Free Biopharma Daily Stock Updates - 06/23/22

$XBI $76.23 | +6.18%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.

Table of Contents:

Covid Updates

#NVAX +14% Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17

#NVAX +14% Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

#NVAX +14% Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over

Pipeline Updates

#NMTR +31.1%

#XXII +31%

#ORMP +27.9%

#QURE +27% uniQure N.V. - uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

#VALN +26.5%

#ANEB +18.5% Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

#CALA +7.5% Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

#BNTX +7.0% BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer

#SRPT +5.1% Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

#EVAX +5.1% Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

#CGEM +4.6% Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

#SCYX +4.3% SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

#GILD +1.7% Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks

#AZN +1.4% ALXN1840 shows rapid and sustained improvement in copper mobilisation from tissues, potentially closing treatment gaps for Wilson disease community

#ALBO +1.3% Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

#XENE -8.6%

#FUSN -15.5% Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1


Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*


Business Updates

#RDUS +21.7% Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

#CMRX +12.4% Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement

#BSGM +13.6% (-25% aftr mrkt) BioSig Announces Proposed Public Offering of Common Stock


Posted by FS/JM



bottom of page